XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
BARCELONA, Spain, May 14 /PRNewswire/ --
- Data from SPIRIT II and III Clinical Trials Also Show Improvement in Vessel Renarrowing with XIENCE V Compared to TAXUS in Patients with Small Vessels
Data presented today from an independent pooled subset analysis of Abbott's SPIRIT II and SPIRIT III clinical trials demonstrated a clinically significant 51 percent reduction in major adverse cardiac events (MACE) with the XIENCE(TM) V Everolimus Eluting Coronary Stent System compared to the TAXUS(R) paclitaxel-eluting coronary stent system in patients with small vessels out to one year. The data…